Comparing the efficacy of add-on daylight vs. artificial light therapy for inpatients with Major Depressive Disorder

Comparing the efficacy of add-on daylight vs. artificial light therapy for inpatients with Major Depressive Disorder - ARISE

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00038260

Enrollment

113

Registered

2025-10-29

Start date

2025-12-03

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICD-10 F32-F33 F32 F33

Interventions

Group 1: Daylight therapy, 35 days, 40 minutes per day Group 2: Therapy lamp, 35 days, 40 minutes per day Group 3: Placebo lamp, 35 days, 40 minutes per day

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: inpatient on psychiatric ward of the UPK Basel speaking and understanding German ability to understand study information and give written consent (according to HRA, Art. 23) current diagnosis of MDD according to ICD-11 criteria (ICD-11 code: 6A7)

Exclusion criteria

Exclusion criteria: psychotic symptoms bipolar disorder (Type 1 and 2) inability to follow study instructions and/or participate in daily therapy program on ward (GAF score < 30)/incapability of judgement acute suicidal thoughts, plans, or recent attempt (previous 6 months) ongoing ECT therapy ongoing nordic walking therapy treatment with Ketamine / S-Ketamine pregnancy drugs/diseases associated with photosensitivity severe ophthalmological diseases

Design outcomes

Primary

Measure	Time frame
Hamilton Depression Rating Scale-17	—

Secondary

Measure	Time frame
Dim light melatonin onset (DLMO), melatonin offset (MOff) Rest-activity-patterns (actigraphy) Light dosimetry (light sensor) Montgomery-Asberg Depression Rating Scale (MADRS) Beck Depression Inventory (BDI) Visual Analog Scale for Depression Morningness-Eveningness Questionnaire (MEQ) Pittsburgh Sleep Quality Index (PSQI) Epworth Sleepiness Scale (ESS) Insomnia Severity Index (ISI) Positive and Negative Affect Scale (PANAS) Global Assessment of Functioning (GAF) Treatment Expectation Questionnaire (TEX-Q) Systematic Assessment for Treatment Emergent Effects (SAFTEE)	—

Measure

Time frame

Dim light melatonin onset (DLMO), melatonin offset (MOff) Rest-activity-patterns (actigraphy) Light dosimetry (light sensor) Montgomery-Asberg Depression Rating Scale (MADRS) Beck Depression Inventory (BDI) Visual Analog Scale for Depression Morningness-Eveningness Questionnaire (MEQ) Pittsburgh Sleep Quality Index (PSQI) Epworth Sleepiness Scale (ESS) Insomnia Severity Index (ISI) Positive and Negative Affect Scale (PANAS) Global Assessment of Functioning (GAF) Treatment Expectation Questionnaire (TEX-Q) Systematic Assessment for Treatment Emergent Effects (SAFTEE)

—

Countries

Switzerland

Contacts

Public ContactCorrado Garbazza

Universitäre Psychiatrische Kliniken Basel

corrado.garbazza@upk.ch+41 61 325 5144

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026